DNLI FY 2024 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

DNLIDenali Therapeutics Inc.

$3B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$487M

Net Income

-$423M

EPS (Diluted)

$-2.57

Cash Flow

Operating Cash Flow

-$348M

Free Cash Flow

-$364M

Stock-Based Comp.

$103M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$144M

Stockholders' Equity

$1.2B

Cash & Equivalents

$175M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$331M	-100.0%
Gross Profit	$0	$331M	-100.0%
Operating Income	-$487M	-$197M	-147.8%
Net Income	-$423M	-$145M	-191.1%